CBSET Inc.

CBSET Inc. , based in the US, specializes in preclinical science, providing a wide range of services including in vivo testing, histopathological analysis, and computational modeling for medical device and pharmaceutical evaluations. Founded in 2006 in Lexington, US, CBSET Inc. focuses on preclinical science services.

The company has engaged in one transaction as of October 2025, securing a majority stake acquisition by Arlington Capital Partners to enhance its market positioning. CBSET specializes in integrated preclinical science, offering a comprehensive suite of services that includes in vivo testing, histopathological analysis, and computational modeling. These core offerings are designed to address complex scientific queries related to medical device evaluation, drug kinetics, and therapeutic safety and efficacy. The company has developed innovative techniques for the implantation of devices and the evaluation of pharmacology, toxicity, and biodistribution of drugs and cell-based therapeutics.

CBSET's clients include developers of novel diagnostic and therapeutic medical devices, as well as pharmaceutical companies working on new drug therapies. The company serves a diverse client base primarily in North America and Europe, leveraging its specialized expertise to facilitate regulatory compliance and scientific advancement in the medical field. CBSET generates revenue through contracts with clients that typically involve detailed preclinical testing and evaluation services. The business model primarily operates on a B2B basis, collaborating with companies in the medical device and pharmaceutical sectors.

Transactions are structured around specific projects, with pricing reflecting the complexity and scope of the studies conducted. Clients may engage CBSET for comprehensive service packages that include medical device testing and drug evaluation, often accompanied by ongoing support and consultation. While specific pricing details are proprietary, the company's offerings are tailored to meet the regulatory requirements of its clients’ technologies, ensuring high-value services in the preclinical evaluation landscape. In October 2025, Arlington Capital Partners acquired a majority stake in CBSET Inc.

This acquisition is intended to strengthen CBSET's market position. The company is focused on expanding its services and geographic reach, targeting additional markets in Europe and North America by the end of 2026.